Adaptive Biotechnologies Corporation has announced the launch of its ImmuneRACE virtual clinical trial as part of a broader effort with Microsoft Corporation. The goal of the collaboration was to accelerate the measurement of the immune response to the COVID-19 virus. The study involves 1000 participants from the United States.
Adaptive Biotechnologies Corporation has announced the launch of its ImmuneRACE virtual clinical trial as part of a broader effort with Microsoft Corporation. The goal of the collaboration was to accelerate the measurement of the immune response to the COVID-19 virus. The study involves 1000 participants from the United States. 
news.microsoft.com
English (US) 